Pipeline
We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.
Robust R&D Pipeline with significant potential
Near-term and long-term pipeline, securing launches over the coming years.
Cancer Therapeutics
Infigratinib2
2nd Line Cholangiocarcinoma3
1st Line Cholangiocarcinoma
Adjuvant Urothelial Cancer
HM064
Solid Tumors with RET Abnormalities
GPX4 inhibitor5
Multiple tumors
Cancer Supportive Care
Fosnetupitant IV
Fosnetupitant - Palonosetron
Pediatric CINV6
Fosnetupitant - Palonosetron IV
China - CINV6,7
Anamorelin8
Cancer Anorexia-Cachexia in NSCLC9 patients
China – Cancer Anorexia-Cachexia in NSCLC9 patients
Other
HM04
Ghrelin Receptor Antagonist - Prader-Willi Syndrome
HM0110
Ghrelin Receptor Agonist
Notes
The safety and efficacy of the product candidates in the above table have not been established. There is no guarantee that they will receive health authority approval or become commercially available in any country for the uses being investigated.
- Regulatory: Marketing authorization application upcoming or submitted
- lnfigratinib is developed globally by Helsinn Healthcare SA in all fields of use except for skeletal dysplasias and except in the following territories: Mainland China, Hong Kong and Macau
- Approved in U.S., Canada and Australia
- HM06 is co-developed by Helsinn Healthcare SA and Taiho Pharmaceutical Co. Ltd.
- GPX4 inhibitor is co-developed by Helsinn Healthcare SA and BridgeBio Pharma, Inc.
- Chemotherapy-Induced Nausea and Vomiting
- Approved in multiple territories, including USA and EU
- Approved in Japan
- Non-Small Cell Lung Cancer
- HM01 is developed by Helsinn’s partner, AnaCardio